When and How to Treat Essential Thrombocythemia

Barbui, Tiziano; Finazzi, Guido
July 2005
New England Journal of Medicine;7/7/2005, Vol. 353 Issue 1, p85
Academic Journal
Comments on how to treat essential thrombocythemia, which involves clonal hematopoietic stem cells. Details of risk factors for thrombotic events in patients with essential thrombocythemia including age; Use of hydroxyurea as a treatment for thrombocythemia; Details of a study conducted by Harrison et al.; Concerns regarding transformation to acute myelogenous leukemia.


Related Articles

  • Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Jillella, A P; Kallab, A M; Kutlar, A // Bone Marrow Transplantation;10/15/2000, Vol. 26 Issue 8, p925 

    Autoimmune thrombocytopenia after high-dose chemotherapy and autologous bone marrow/peripheral blood stem cell transplantation occurs infrequently and only six cases meeting the criteria have been reported in the literature. All six of these patients had either acute myelogenous leukemia (AML)...

  • Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. Heinzinger, M; Waller, C F; Rosenstiel, A; Scheid, S; Burger, K J; Lange, W // Leukemia (08876924);Mar98, Vol. 12 Issue 3, p333 

    Coexistence of Philadelphia chromosome (Ph)-negative, primitive hematopoietic progenitor cells with their malignant counterparts in chronic myelogenous leukemia (CML) has been reported. As most of the Ph-negative progenitor cells do not express the HLA-DR antigen, selection of them might be...

  • Selection of BCR/ABL-negative stem cells from marrow or blood of patients with chronic myeloid leukemia. Guyotat, D; Wahbi, K; Viallet, A; Piselli, S; Campos, L // Leukemia (08876924);Jul99, Vol. 13 Issue 7, p991 

    Philadelphia (Ph) or BCR/ABL-negative cells with immature phenotype (CD34-positive, DR-negative) can be recovered from patients with chronic myeloid leukemia (CML) in chronic phase. We used the technique described by Berardi et al (Science 1995; 267: 104-108) to select stem cells from marrow or...

  • Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia? Barak, Avital F.; Bonstein, Lilach; Lauterbach, Roy; Naparstek, Elizabeth; Tavor, Sigal // Hematology Reviews;2011, Vol. 3 Issue 3, p95 

    The outcome and quality of life of chronic myeloid leukemia (CML) patients has remarkably changed with the treatment of tyrosine kinase inhibitors (TKIs). Currently, hematopoietic stem cell transplantation (HSCT) is considered mainly as a third line salvage therapy in cases of TKIs resistance or...

  • Stem cell biomarkers in chronic myeloid leukemia. Xiaoyan Jiang; Yun Zhao; Forrest, Donna; Smith, Clayton; Eaves, Allen; Eaves, Connie // Disease Markers;2008, Vol. 24 Issue 4/5, p201 

    Chronic myeloid leukemia (CML) is a clonal multi-step myeloproliferative disease that is initially produced and ultimately sustained by a rare subpopulation of BCR-ABL^{+} cells with multi-lineage stem cell properties. These BCR-ABL^{+} CML stem cells are phenotypically similar to normal...

  • High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia. Narimatsu, H.; Emi, N.; Kohno, A.; Iwai, M.; Yanada, M.; Yokozawa, T.; Saito, S.; Shimada, K.; Kiyoi, H.; Naoe, T.; Yamamoto, K.; Morishita, Y. // Bone Marrow Transplantation;Oct2007, Vol. 40 Issue 8, p773 

    Secondary failure of platelet recovery (SFPR), which is a delayed decline in platelet count after primary recovery following myeloablative hematopoietic SCT, is a significant problem in allogeneic SCT. However, its clinical characteristics have not been well described in autologous SCT for acute...

  • Stem cells: the challenge and opportunities. Messner, H. A. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS57 

    Recent studies have clearly identified that hematopoietic stem cells (HSC) are part of a hierarchical organization defined by cells able to initiate long-term repopulation (LT-HSC) of injured BM followed by populations with transient repopulation ability. As HSCs are able to supply blood cells...

  • DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Garçon, L.; Libura, M.; Delabesse, E.; Valensi, F.; Asnafi, V.; Berger, C.; Schmitt, C.; Leblanc, T.; Buzyn, A.; Macintyre, E. // Leukemia (08876924);Aug2005, Vol. 19 Issue 8, p1338 

    The t(6;9)(p23;q34) is a recurrent chromosomal abnormality observed in 1% of acute myelogenous leukemia (AML), which generates a fusion transcript between DEK and CAN/NUP214 genes. We used a DEK-CAN real-time quantitative (RQ)-PCR strategy to analyze 79 retrospective and prospective samples from...

  • Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Platzbecker, U.; Thiede, C.; Füssel, M.; Geissler, G.; Illmer, T.; Mohr, B.; Hänel, M.; Mahlberg, R.; Krümpelmann, U.; Weissinger, F.; Schaich, M.; Theuser, C.; Ehninger, G.; Bornhäuser, M. // Leukemia (08876924);Apr2006, Vol. 20 Issue 4, p707 

    There is substantial need to improve the outcome of patients with high-risk acute myeloid leukemia (AML). The clinical trial reported here investigated a new approach of up-front allogeneic hematopoietic stem cell transplantation (HSCT), provided a median of 40 days (range 22–74) after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics